We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
07 Dec 2020 - 11 Dec 2020
09 Dec 2020 - 18 Dec 2020
Virtual Venue

Structural Septal Device Relieves Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 03 Oct 2018
Print article
Image: A small interatrial shunt helps relieve heart failure symptoms (Photo courtesy of Corvia Medical).
Image: A small interatrial shunt helps relieve heart failure symptoms (Photo courtesy of Corvia Medical).
A novel shunt forms a passage between the left and right atria, enabling the left atrium to decompress at rest and physical activity, lowering left atrial pressure.

The Corvia Medical (Tewksbury, MA, USA) Interatrial Shunt Device (IASD) is an innovative transcatheter implant intended for diastolic heart failure (HF) patients with preserved ejection fraction (HFpEF) or mid-range (HFmrEF) ejection fraction. After creating a small opening in the atrial septum, the IASD implant is deployed, forming a permanent passage between the atria and facilitating continuous and dynamic decompression of the left atrium. As a result, HF symptoms and quality of life are improved and HF hospitalization rates are reduced.

One-year follow-up data of the IASD clinical study, held in 64 patients implanted at 18 centers in eleven countries, demonstrated shunt patency for all participants who received the implant. Study endpoints, as measured by exercise pulmonary capillary wedge pressure (PCWP) reduction, showed a reduction in New York Heart Association (NYHA) class. Procedural safety, assessed by major adverse cardiovascular, cerebral, or renal events (MACCRE), showed that the IASD is also safe. The study was presented at the European Society of Cardiology (ESC) annual congress, held during August 2018 in Munich (Germany).

“The clinical study is of tremendous interest to me, because HFpEF is a clinical problem for which there is no effective therapy,” said co-lead author and study presenter Ted Feldman, MD, of Evanston Hospital (IL, USA). “We've now studied the IASD in several consecutive trials. The early single-arm studies demonstrated that people felt better and their exercise capacity improved. Now, a sham-controlled randomized study conclusively proves the mechanism of action and again suggests clinical efficacy in midterm follow-up.”

HFpEF accounts for approximately 50% of all HF, affecting more than 6.2 million people in the United States and Europe, but treatment options remain limited, consisting mainly of diuretics and fluid balance control. People with HFpEF suffer from difficulty breathing, find simple daily activities tiring (if not impossible), and are frequently hospitalized, with a resultant dramatic reduction in their quality of life. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in left atrial pressure, in particular during exercise.

Related Links:
Corvia Medical

Print article


Copyright © 2000-2020 Globetech Media. All rights reserved.